Overview

Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma

Status:
Unknown status

Trial end date:
2017-05-01

Target enrollment:

Participant gender:

Summary

In this phase II study, the investigators aim to evaluated the efficacy and toxicity of definitive concurrent chemoradiotherapy (CCRT) with docetaxel plus cisplatin (DP regimen) versus 5-fluorouracil plus cisplatin (PF regimen) in patients with esophageal squamous cell carcinoma (ESCC).

Phase:

Phase 2

Details

Lead Sponsor:

Zhu Yujia

Treatments:

Cisplatin
Docetaxel
Fluorouracil